Type 1 Diabetes Clinical Trial
— ENHANCED1Official title:
Proof-of-concept Study for the Integration of Physical Activity Into the Clinical Decision Process of Physically Active People With Type 1 Diabetes
Every person with type 1 diabetes needs personalized advice to integrate physical activity into daily diabetes management. The purpose of this study is to collect data on food intake, physical activity, glucose levels and insulin delivery from people with type 1 diabetes who are physically active. At least 25 people with type 1 diabetes will be asked to perform 25 sports activities of at least half an hour, wear an activity tracker (day and night) and chest strap (during sports activities), and log data on food intake, periods and type of physical activity, and feelings (e.g., sick, stress) in a diary app. Diabetes data such as insulin administration and sensor data will be collected through diabetes management platforms. The primary endpoint involves a database containing data on glucose, insulin administration, physical activity, and food intake of people with type 1 diabetes for statistical analyses and visualizations regarding the relationship between physical activity and blood glucose response.
Status | Recruiting |
Enrollment | 25 |
Est. completion date | March 1, 2023 |
Est. primary completion date | March 1, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Signed informed consent - 18-80 years old - Type 1 diabetes =1 year - Using a CGM for more than 6 months - Using insulin (insulin pens, insulin pumps or hybrid closed-loop systems) to manage glycaemia for more than 6 months - No use of adjunctive therapies, such as SGLT2-inhibitors or GLP-1 analogues - No known diabetic gastroparesis - HbA1c of the last two diabetes consultations are both <10% - Being physically active at least twice a week on two separate days for 30 consecutive minutes Exclusion Criteria: - Age <18 years or >80 years - People with type 2 diabetes, people with secondary diabetes - Begin treatment with insulin (insulin pens, insulin pumps or hybrid closed-loop systems) less than 6 months before inclusion - Not using CGM prior to inclusion - Known diabetic gastroparesis - HbA1c > 10% during one of the last two diabetes consultations - Not willing to use an activity tracker, the diary app or the food app - Not being physically active on a regular basis |
Country | Name | City | State |
---|---|---|---|
Belgium | UZ Leuven | Leuven |
Lead Sponsor | Collaborator |
---|---|
prof dr Pieter Gillard | University Colleges Leuven Limburg |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Database which contains insulin data (insulin dose over time) retrieved from diabetes management platforms. | Through study completion (after 25 sport activities), an average of 6 weeks | ||
Primary | Database which contains glucose data (glycemic values over time) retrieved from diabetes management platforms. | Through study completion (after 25 sport activities), an average of 6 weeks | ||
Primary | Database which contains physical activity data (type of activity) retrieved from the activity tracker and chest strap. | Through study completion (after 25 sport activities), an average of 6 weeks | ||
Primary | Database which contains physical activity data (intensity of activity) retrieved from the activity tracker and chest strap. | Through study completion (after 25 sport activities), an average of 6 weeks | ||
Primary | Database which contains physical activity data (duration of activity) retrieved from the activity tracker and chest strap. | Through study completion (after 25 sport activities), an average of 6 weeks | ||
Primary | Database which contains food intake data (timing of food) retrieved from the diary app. | Through study completion (after 25 sport activities), an average of 6 weeks | ||
Primary | Database which contains food intake data (amount of food in grams) retrieved from the diary app. | Through study completion (after 25 sport activities), an average of 6 weeks | ||
Primary | Database which contains food intake data (type of food) retrieved from the diary app. | Through study completion (after 25 sport activities), an average of 6 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|
||
Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 | |
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |